Healthy Returns: A Safer Future | March 10, 2021 | 12:00pm ET
On the one year anniversary of the WHO declaring a pandemic, CNBC takes a look at how far we’ve come, and what needs to be done to make for a safer future for all.
Meg Tirrell speaks to Dr. Luciana Borio, In-Q-Tel VP and Former FDA Acting Chief Scientist, and Dr. Scott Gottlieb, Former FDA Commissioner about the year that was and building a safer future. They explore where we are as an immunized nation with the roll out of the third FDA-authorized vaccine, how the threat of Covid is evolving and the road to reopening.
Hosted by CNBC’s Senior Health & Science Reporter, Meg Tirrell, and featuring interviews with healthcare CEOs, investors & technologists addressing the lasting effects of COVID-19, Healthy Returns livestreams are broadcast on CNBC.com and CNBC social handles.
HOW TO WATCH:
Watch our 2020 Event Highlights
Visit cnbc.com/healthy-returns to find in-depth coverage from the CNBC team about health care innovation.
Luciana Borio is VP of In-Q-Tel and Former Acting Chief Scientist of FDA.
Scott Gottlieb, MD is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety.
Dr. Gottlieb is an aggressive advocate for advancing the health of patients, promoting healthcare access, and driving innovation. The agency’s historic and prolific advances in new policy distinguished his tenure as the FDA’s commissioner, in addition to a record-setting number of approvals of novel drugs, medical devices, and generic medicines.
Under his leadership, the FDA advanced new frameworks for the modern and safe and effective oversight of gene therapies, cell based regenerative medicines, targeted drugs, and digital health devices. The agency implemented new reforms to standardize drug reviews and make historic improvements of post market data collection and the use of real world evidence. He promoted policies to reduce death and disease from tobacco, improve food innovation and safety, and aggressively confront addiction crises.
Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he helped advance policies to improve healthcare quality and promote the effective use of new medical technologies. A healthcare futurist, he works as a venture capitalist and has been a founder and board member to companies that have developed new medicines and advance the delivery of healthcare.
Dr. Gottlieb is widely published in leading medical journals and periodicals, including The Wall Street Journal, The New York Times, and The Washington Post. He has held editorial positions on the British Medical Journal and the Journal of the American Medical Association. Fortune Magazine recognized him as one of the “World’s 50 Greatest Leaders” in 2018 and again in 2019. Modern Healthcare named Dr. Gottlieb as one of the “Most Influential Physician Executive and Leaders” in its annual survey of 50 physician executives, and Time magazine named Gottlieb one of its “50 People Transforming Healthcare in 2018.”
Dr. Gottlieb was a practicing hospitalist and a Clinical Assistant Professor at the New York University School of Medicine. He is an elected member of the National Academy of Medicine and a Resident Fellow at the American Enterprise Institute in Washington, DC.
Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to CNBC.com and is based at the network's global headquarters in Englewood Cliffs, N.J.
Tirrell has covered development of new drugs for Alzheimer's, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome, and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.
Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek.
She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.
Healthy Returns: A Safer Future
March 10, 2021 | 12:00pm ET
On the one year anniversary of the WHO declaring a pandemic, CNBC takes a look at how far we’ve come, and what needs to be done to make for a safer future for all. Meg Tirrell speaks to Dr. Luciana Borio, In-Q-Tel VP and Former FDA Acting Chief Scientist, and Dr. Scott Gottlieb, Former FDA Commissioner about the year that was and building a safer future. They explore where we are as an immunized nation with the roll out of the third FDA-authorized vaccine, how the threat of Covid is evolving and the road to reopening.
Watch all of our Healthy Returns livestreams here
REGISTER FOR THE MAY 11, 2021 SUMMIT.
Subscribe to our Healthy Returns newsletter for exclusive insights on the biggest health care news from our reporters, delivered straight to your inbox every Friday.
Visit cnbc.com/healthy-returns for relevant content from the event and all-things health care investing and innovation.
For additional questions, email events@cnbc.com.
Change Healthcare is a leading independent healthcare technology company, focused on insights, innovation and accelerating the transformation of the healthcare system through the power of the Change Healthcare platform. We provide data and analytics-driven solutions to improve clinical, financial, administrative, and patient engagement outcomes in the U.S. healthcare system.
Our platform and comprehensive suite of software, analytics, technology enabled services and network solutions drive improved results in the complex workflows of healthcare system payers and providers by enhancing clinical decision making, simplifying billing, collection and payment processes, and enabling a better patient experience.
Our Intelligent Healthcare Network is one of the largest clinical and financial healthcare networks in the U.S., facilitating over 15 billion transactions and approximately $1.5 trillion in adjudicated claims, or more than one-third of all U.S. healthcare expenditures. Our customer base includes approximately 2,400 government and commercial payer connections, 1,000,000 physicians, 125,000 dentists, 39,000 pharmacies, 6,000 hospitals and 700 laboratories.
Dr. Anthony Fauci is Director of the National Institute of Allergy and Infectious Diseases (NIAID).
Dr. Moncef Slaoui is Chief Advisor of Operation Warp Speed.
Martine Rothblatt is Chairman & CEO of United Therapeutics, a biotechnology company she started to save the life of one of her daughters. The company offers FDA approved medicines for pulmonary hypertension and neuroblastoma and is working on manufacturing an unlimited supply of transplantable organs.
Dr. Rothblatt previously created and led Sirius XM as its Chairman & CEO, and launched other satellite systems for navigation and international television broadcasting. In the field of aviation her Sirius XM satellite system enhances safety with real-time digital weather information to pilots in flight nationwide. She also designed the world’s first electric helicopter, which in 2018 set Guinness world records for distance and flight duration.
In the legal arena, Dr. Rothblatt led efforts to create transgender health law standards, and to protect privacy and autonomy rights in genetic information via an international treaty. She has Bachelor’s (Communications Studies, Summa Cum Laude), JD and MBA degrees from UCLA, and a Ph.D. in Medical Ethics from the Royal London School of Medicine & Dentistry. Her patented inventions cover aspects of satellite radio, prostacyclin biochemistry and cognitive software. Dr. Rothblatt’s recent books are on xenotransplantation (Your Life or Mine), non-binary gender identity (Transgender to Transhuman) and cyberethics (Virtually Human).
Alex Gorsky is Chairman of the Board and Chief Executive Officer of Johnson & Johnson and Chairman of the Executive Committee, the Company’s senior leadership team. Alex is the seventh person to serve as Chairman and CEO of Johnson & Johnson since it became a publicly traded company in 1944.
Alex began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing and management including assignments in the U.S., Europe, Africa and the Middle East. He progressed through many management posts at J&J, culminating in being named Chief Executive Officer on April 26, 2012 and Chairman of the Board on December 28, 2012.
Under Alex Gorsky’s leadership, Johnson & Johnson continues in its 132nd year to be one of the world’s exceptional corporations. The company was given the #1 ranking on Barron’s Magazine’s 2016 list of the “World’s Most Admired Companies,” and is currently the number one Pharmaceutical company on Fortune Magazine’s list of the “World’s Most Respected Companies.
A longtime advocate of Diversity Inclusion and Veteran’s issues, Alex has been named one of the “100 Most Inspiring Leaders” by Pharma Voice. Most recently, in December of 2017, Alex received the Ripple of Hope Award from the Robert F. Kennedy Human Rights Foundation. And for the past three years, Alex has been on the list of the Highest Rated CEOs on The Glassdoor Employees’ Choice Awards. He has also received the Jackie Robinson Award, Appeal of Conscience Award, the Joseph Wharton Leadership Award and the CADCA Humanitarian of the Year Award.
Alex is a member of the Board of Directors of IBM, the Wharton School of Business Board of Overseers and the Board of Directors of the Business Roundtable.
Alex holds a Bachelor of Science degree from the U.S. Military Academy at West Point, N.Y., and spent six years in the U.S. Army, finishing his military career with the rank of Captain. Alex earned a Master of Business Administration degree from The Wharton School of the University of Pennsylvania in 1996.